



JFW

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Express Mail No. EV482045801US.

Date: March 10, 2006

Name: JoAnne M. Varanelli

Signature:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Andrea Savarino

) Confirmation No.: 7328

Serial No.: 10/783,268

) Art Unit: 1617

Filing Date: February 20, 2004

For: Methods for Treatment of HIV or Malaria
Using Combinations of Chloroquine and
Protease Inhibitors

) Docket No.: 97728.00147

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

In accordance with 37 C.F.R. §1.56, the materials listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. This Information Disclosure Statement is believed to be filed prior to the mailing date of a First Office Action regarding the above-referenced application. Accordingly, no fee is believed to be required. Pursuant to the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for applications filed after June 30, 2003, copies of the U.S. Patent references set forth and cited on form PTO/SB/08 are not enclosed herewith. Copies of the Non-Patent Literature Documents set forth and cited on form PTO/SB/08 are enclosed herewith.


It is respectfully requested the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

In accordance with 37 C.F.R. § 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made; an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b); or an admission that the information cited in the statement is, or is considered to be, prior art.

No fee is believed to be required. However, if any fee is required, or otherwise if necessary to cover any deficiency in fees already paid, authorization is hereby given to charge our Deposit Account No. 50-1402.

Respectfully submitted,

Date: March 10, 2006

By: 
Eric E. Grondahl
Attorney for Applicants
Registration No. 46,741

PTO Correspondence Address:

McCarter & English, LLP
CityPlace I
185 Asylum Street
Hartford, CT 06103
Phone: (860) 275-6704
Fax: (860) 724-3397
ME5535673



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/783,268
		Filing Date	February 20, 2004
		First Named Inventor	Andrea Savarino
		Art Unit	1617
		Examiner Name	WANG, SHENGJUN
Sheet 2	of 2	Attorney Docket Number	97728.00147

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	T ²
	1	Treatment for HIV related inflammation, Treatment Review, May 1995 (no. 18) Abstract	
	2	Hydroxychloroquine+ddl+hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles, AIDS Treatment News, December 3, 1990 (No. 332)	
	3	BOELAET, et al. The Additive I Vitro and Anti-HIV-1 Effect of Chloroquine, When Combined with Zidovudine and Hydroxyurea, Biochemical Pharmacology, 2001, Vol. 61, pages 1531-1535.	
	4	CHUKWUEMEKA, A Management of HIV-Infected Pregnant Patients in Malaria-Endemic Areas; Therapeutic and Safety Considerations in ConComitant Use of Antiviral and Antimalarial Agents, Clinic Therapeutics, 1999, Vol. 21, No 9, 1999, pages 1456-1496	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ME5535776